Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 8, 24 | -0.43 Decreased by -86.96% | -0.25 Decreased by -72% |
| Nov 14, 23 | -2.24 Decreased by -229.41% | -8.17 Increased by +72.58% |
| Aug 14, 23 | -26.28 Decreased by -4.95 K% | -11.19 Decreased by -134.85% |
| May 11, 23 | -0.28 Increased by +98.36% | -7.88 Increased by +96.45% |
| Mar 13, 23 | -0.23 Increased by +100% | -0.42 Increased by +45.24% |
| Nov 14, 22 | -0.68 Increased by +28.42% | -0.25 Decreased by -172% |
| Aug 22, 22 | -0.52 Decreased by -6.48 K% | -0.42 Decreased by -23.81% |
| May 27, 22 | -17.1 Decreased by -28.88 K% | -0.66 Decreased by -2.49 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by N/A% | -1.72 M Increased by +39.32% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0 Decreased by N/A% | -5.55 M Decreased by -19.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -2.38 M Increased by +48.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -3.14 M Increased by +84.8% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -2.84 M Increased by +86.26% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -4.66 M Decreased by -378.53% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -4.66 M Increased by +13.7% | Decreased by N/A% - |
| Mar 31, 22 | 0 Decreased by N/A% | -20.66 M Decreased by -569.76% | Decreased by N/A% Decreased by N/A% |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.